Skip to content

Study · Case report or series · n = 1 · 2025

2 results

Semaglutide-associated drug-induced liver injury: a case report and review of the literature.

Kempster I, Fernandes D, Saeed MS, Sharratt C, Benfield S

Oxford medical case reports28 Sept 2025Cited by 2 (Europe PMC)

PMID41025030 (opens in a new tab)PMCIDPMC12476543 (opens in a new tab)DOI10.1093/omcr/omaf177 (opens in a new tab)PepBankPUB-41025030
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) used to manage type 2 diabetes and, since 2021, for weight loss in individuals with obesity or weight-related comorbidities. It works by enhancing insulin secretion, delaying gastric emptying and reducing appetite. Common side effects include hypoglycaemia, gastrointestinal disturbances, nausea, weight loss and cholelithiasis. While some studies have noted an association with acute kidney injury, reports of liver injury are rare. We present a rare case of drug-induced liver injury in a middle-aged female, associated with transient liver failure after semaglutide use. She presented one month after starting the medication with rapidly worsening liver function tests. Investigations, including a non-invasive liver screen, viral studies, ultrasound and CT imaging, revealed no clear cause. A liver biopsy supported the diagnosis of drug-induced liver injury. The patient improved with supportive treatment and withdrawal of semaglutide. This case underscores the importance of clinician awareness given its increasing, and often unregulated, use for weight loss.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a middle-aged woman, drug-induced liver injury with transient liver failure was associated with semaglutide use, with rapidly worsening liver function tests one month after the start.

    In plain wordsA middle-aged woman developed liver injury with short-term liver failure one month after she started semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseDrug-induced liver injury with transient liver failure
    Study

    n = 1

    Outcome group
    Adverse events · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We present a rare case of drug-induced liver injury in a middle-aged female, associated with transient liver failure after semaglutide use.
    2 context sentences
    Summary · context
    She presented one month after starting the medication with rapidly worsening liver function tests.
    Summary · context
    A liver biopsy supported the diagnosis of drug-induced liver injury.
  2. 02HumanCase report or seriesSafety outcome

    In the same woman, the liver injury improved with supportive treatment and withdrawal of semaglutide.

    In plain wordsThe woman's liver injury improved after semaglutide was stopped and she received supportive care.

    Peptide
    Semaglutide
    Outcome
    DecreaseRecovery after semaglutide withdrawal
    Study

    n = 1

    Outcome group
    Adverse events · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The patient improved with supportive treatment and withdrawal of semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.